Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31225595 | 0.91 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1MAPK1NPC1PKM | |
| SCHEMBL68412 | 0.89 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1MAPK1NPC1PKM | |
| SCHEMBL1107143 | 0.84 | KMT2A (0.56) | CTBP2L3MBTL1ALDH1A1MAPK1NPC1 | |
| SCHEMBL1515865 | 0.84 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1MAPK1NPC1PKM | |
| SCHEMBL4915749 | 0.84 | EGFR (0.44) | L3MBTL1ALDH1A1MAPK1PKMEGFR | |
| SCHEMBL7708934 | 0.84 | GAA (0.41) | CTBP2ALDH1A1MAPK1PKMNFKB1 | |
| SCHEMBL2745464 | 0.83 | CYP4F2 (0.57) | ALDH1A1CA12CA1CA7CA9 | |
| SCHEMBL3813772 | 0.83 | CTDSP1 (0.47) | CTBP2CA12CA1CA2CA7 | |
| SCHEMBL31225506 | 0.83 | MMP3 (0.48) | L3MBTL1ALDH1A1NPC1PKMNFKB1 | |
| SCHEMBL1401401 | 0.83 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1MAPK1NPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2025137606-A1 | (HETERO)ARYL NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4543439-A2 | NRF2 PROTEIN DEGRADERS | Ganymede Oncology, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024183807-A1 | ARYL FUSED IMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | 哈尔滨三联药业股份有限公司 | 2024-09-12 | — | — | WO | disclosed |
| CN-118619885-A | Arylimidazole compound and medical application thereof | 哈尔滨三联药业股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-111146496-B | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池股份有限公司 | 2021-07-13 | — | — | CN | disclosed |
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | disclosed |
| US-5153214-A | Treating cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0462830-A2 | Cyclic ether derivatives | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
| WO-1991019700-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-26 | — | — | WO | disclosed |
| US-5025025-A | Cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0405391-A1 | Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof | CIBA-GEIGY AG (CH) | 1991-01-02 | — | — | EP | disclosed |
| US-4493823-A | USING CARBOXYBENZENE COMPOUND | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-01-15 | — | — | US | disclosed |
| US-4285958-A | ANTIALLERGENS; ANTIHISTAMINES; BRONCHODILATOR AGENTS | RICHARDSON-MERRELL INC. (US) | 1981-08-25 | — | — | US | disclosed |
| US-4254130-A | ANTIALLERGENS | RICHARDSON-MERRELL INC. (US) | 1981-03-03 | — | — | US | disclosed |
| US-4208335-A | MICROBIOCIDES | RIKER LABORATORIES, INC. (US) | 1980-06-17 | — | — | US | disclosed |
| US-4143154-A | ANTI-MICROBIAL 2-NITRO-3-PHENYL BENZOFURANS SUBSTITUTED BY CARBOXY CONTAINING GROUP | RIKER LABORATORIES, INC. (US) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | CTBP2 1484/4885L3MBTL1 1283/4885ALDH1A1 1094/4885 |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | CTBP2 2765/4885L3MBTL1 89/4885ALDH1A1 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.